Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Advanced or Metastatic ER+ Breast Cancer 1

Interventions

Cyclophosphamide 391Carboplatin 345pembrolizumab 332Gemcitabine 332Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 288Bevacizumab 254Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 191fludarabine 178Oxaliplatin 178Pemetrexed 154Doxorubicin 153Irinotecan 149Leucovorin 145Etoposide 144Cytarabine 134Cetuximab 131fludarabine phosphate 129Bortezomib 129Lenalidomide 126Erlotinib Hydrochloride 121Filgrastim 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × LSZ102 × Clear all
NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Novartis

Phase 1 Terminated
199 enrolled
Breast

Advanced or Metastatic ER+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡